Skip to main content

Table 2 Odds ratios for cancer in PLHIV by complete case analysis and by weighted analysis

From: The burden of cancers associated with HIV in the South African public health sector, 2004–2014: a record linkage study

Cancer Complete case Weighted
Odds Ratio (95% CI) p-value Odds Ratio (95% CI) p-value
ADC 4.50 (4.35–4.65) < 0.0001 3.46 (3.33–3.59) < 0.0001
 Kaposi 134 (111–161) < 0.0001 98.8 (80.9–120) < 0.0001
 Cervix 1.70 (1.63–1.77) < 0.0001 1.68 (1.60–1.76) < 0.0001
 NHL 2.73 (2.56–2.91) < 0.0001 2.89 (2.71–3.08) < 0.0001
  Burkitt’s lymphoma 6.48 (5.21–8.07) < 0.0001 7.83 (6.38–9.62) < 0.0001
  Non-Hodgkins NOS 4.26 (3.4–5.34) < 0.0001 4.85 (3.88–6.07) < 0.0001
  DLBCL 2.93 (2.67–3.22) < 0.0001 3.27 (3.00–3.59) < 0.0001
  DILBCL 12.1 (9.02–16.3) < 0.0001 12.0 (8.91–16.1) < 0.0001
  Follicular 0.65 (0.49–0.87) 0.004 0.73 (0.55–0.98) 0.038
NADC 0.26 (0.25–0.26) < 0.0001 0.36 (0.35–0.38) < 0.0001
  Virus-related NADC 0.75 (0.71–0.78) < 0.0001 0.77 (0.73–0.82) < 0.0001
 Anus 1.63 (1.33–2.00) < 0.0001 1.61 (1.30–1.99) < 0.0001
 Hodgkin’s lymphoma 1.22 (1.09–1.37) < 0.0001 1.43 (1.27–1.61) < 0.0001
 Liver 0.45 (0.39–0.53) < 0.0001 0.51 (0.42–0.61) < 0.0001
 Vulva 1.94 (1.67–2.25) < 0.0001 1.82 (1.58–2.10) < 0.0001
 Vagina 0.83 (0.67–1.03) 0.09 0.88 (0.70–1.11) 0.29
 Penis 2.35 (1.85–2.99) < 0.0001 2.06 (1.63–2.61) < 0.0001
 Lip, oral cavity and Pharynx (C00-C14) 0.55 (0.50–0.59) < 0.0001 0.67 (0.61–0.73) < 0.0001
 Gum 0.74 (0.41–1.36) 0.34 0.90 (0.46–1.76) 0.76
 Lip 2.72 (1.71–4.32) < 0.0001 3.47 (1.95–6.16) < 0.0001
 Mouth 0.56 (0.49–0.66) < 0.0001 0.63 (0.53–0.75) < 0.0001
 Naso-oropharynx 0.48 (0.42–0.56) < 0.0001 0.57 (0.48–0.68) < 0.0001
 Salivary gland 0.65 (0.51–0.82) < 0.0001 0.71 (0.54–0.93) 0.01
 Tongue 0.51 (0.43–0.60) < 0.0001 0.57 (0.47–0.70) < 0.0001
 Virus-unrelated NADC 0.30 (0.29–0.31) < 0.0001 0.43 (0.42–0.45) < 0.0001
 BCC 1.27 (1.08–1.49) < 0.0001 1.39 (1.17–1.67) < 0.0001
 Bladder 0.74 (0.61–0.89) < 0.0001 0.86 (0.69–1.08) 0.2
 Bone 0.32 (0.26–0.40) < 0.0001 0.41 (0.30–0.54) < 0.0001
 Brain 0.27 (0.22–0.34) < 0.0001 0.34 (0.26–0.43) < 0.0001
 Colorectal 0.43 (0.38–0.47) < 0.0001 0.55 (0.48–0.62) < 0.0001
 Eye 5.9 (5.11–6.82) < 0.0001 7.73 (6.60–9.05) < 0.0001
  Conjunctiva 21.5 (16.3–28.4) < 0.0001 20.8 (15.2–28.5) < 0.0001
 Haematology 0.49 (0.37–0.65) < 0.0001 0.58 (0.43–0.80) < 0.0001
 Kidney 0.18 (0.15–0.21) < 0.0001 0.23 (0.19–0.29) < 0.0001
 Larynx 0.56 (0.49–0.64) < 0.0001 0.62 (0.53–0.72) < 0.0001
 Leukaemia 0.25 (0.23–0.28) < 0.0001 0.33 (0.30–0.37) < 0.0001
 Lung 0.52 (0.48–0.57) < 0.0001 0.62 (0.56–0.68) < 0.0001
 Melanoma 0.77 (0.63–0.93) 0.01 0.95 (0.76–1.20) 0.69
 Mesothelioma 0.50 (0.34–0.75) < 0.0001 0.51 (0.32–0.80) < 0.0001
 Myeloma 0.61 (0.52–0.71) < 0.0001 0.75 (0.63–0.89) < 0.0001
 Oesophagus 0.57 (0.52–0.64) < 0.0001 0.58 (0.52–0.66) < 0.0001
 Pancreas 0.43 (0.33–0.58) < 0.0001 0.60 (0.42–0.84) < 0.0001
 SCC Skin 1.83 (1.64–2.04) < 0.0001 1.88 (1.67–2.11) < 0.0001
 Skin 0.95 (0.77–1.16) 0.6 1.11 (0.87–1.41) 0.41
 Small intestines 0.33 (0.23–0.48) < 0.0001 0.35 (0.24–0.53) < 0.0001
 Stomach 0.43 (0.37–0.49) < 0.0001 0.58 (0.49–0.70) < 0.0001
 Thyroid 0.75 (0.59–0.95) 0.02 1.01 (0.74–1.37) 0.97
 Uterus 0.38 (0.34–0.43) < 0.0001 0.44 (0.39–0.50) < 0.0001
 Breast 0.43 (0.41–0.45) < 0.0001 0.50 (0.47–0.53) < 0.0001
 Placenta 0.85 (0.58–1.24) 0.39 1.05 (0.70–1.56) 0.83
 Prostate 0.85 (0.76–0.95) < 0.0001 0.95 (0.84–1.08) 0.46
 Testis 0.37 (0.26–0.53) < 0.0001 0.48 (0.32–0.74) < 0.0001
 Poorly specified histology at any site 0.82 (0.77–0.88) < 0.0001 0.95 (0.88–1.03) 0.2
  1. OR Odds ratios determined using logistic regression models adjusting for age, gender, race, province and year of cancer diagnosis, NHL non-Hodgkin’s lymphoma, DLBCL Diffuse large B-cell lymphoma, DILBCL Diffuse Immunoblastic Large B-cell lymphoma, NOS Not Otherwise Specified, BCC Basal cell carcinoma, ADC AIDS defining cancer, NADC non-AIDS defining cancer, SCC skin squamous cell carcinoma of the skin, Virus-related NADCs liver cancer (hepatitis viruses), penis, vulva, vagina, anal, lip, mouth, gum, salivary gland and tonsil (Human Papilloma Virus (HPV) associated malignancies other than cervix), and Hodgkin’s lymphoma and nasopharyngeal cancer (Epstein Barr Virus (EBV)). The weighted analysis included inverse probability weights estimated from known HIV status age, gender, cancer diagnosis and cancer diagnosis year